Hanna Bandos

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy”.

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

New England Journal of Medicine(2025)10.1056/nejmoa2414859

N/A

1.2DataRank · unranked

93 citations

Hanna Bandos, Julia White, Thomas B. Julian, Atif J. Khan, Simona F. Shaitelman +23 more

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.502

N/A

0.832DataRank · unranked

16 citations

Hanna Bandos, Peter C. Lucas, L. J. van ‘t Veer, Jia-Perng Jennifer Wei, Charles E. Geyer +15 more

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Journal of Clinical Oncology(2024)10.1200/jco.23.02344

N/A

0.646DataRank · unranked

17 citations

Jieling Miao, Lajos Pusztai, Matthew P. Goetz, Priya Rastogi, Patricia A. Ganz +17 more

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Breast Cancer Research and Treatment(2022)10.1007/s10549-021-06417-y

N/A

0.593DataRank · unranked

10 citations

Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher +13 more

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

JNCI Cancer Spectrum(2025)10.1093/jncics/pkaf032

N/A

0.208DataRank · unranked

3 citations

Sungjin Kim, N. Lynn Henry, Ron D. Hays, Vinícius F. Calsavara, Michael Luu +11 more

Talking numbers: how women and providers use risk scores during and after risk counseling – a qualitative investigation from the NRG Oncology/NSABP DMP-1 study

BMJ Open(2023)10.1136/bmjopen-2023-073138

N/A

0.104DataRank · unranked

1 citations

Christine M. Gunn, Patricia A. Parker, Angela Fagerlin, Tracy A. Battaglia, Therese B. Bevers +5 more

Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.501

N/A

0DataRank · unranked

22 citations

Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas +14 more

PRESCIENTai, an AI-based digital histopathological image signature for risk of late distant recurrence and extended endocrine therapy (EET) benefit in hormone receptor–positive breast cancer.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.1556

N/A

0DataRank · unranked

0 citations

Ming Chen, Tanner J. Freeman, Nicolas Stransky, Md. Samiur Rahman, Mark Miglarese +14 more

Definitive Results of a Phase III Adjuvant Trial Comparing Six Cycles of FEC-100 to Four Cycles of AC in Women with Operable Node-negative Breast Cancer: The NSABP B-36 Trial (NRG Oncology)

Research Square(2021)10.21203/rs.3.rs-841103/v1

N/A

0DataRank · unranked

3 citations

Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher +13 more

Five- or 10-year colonoscopy for 1-2 non-advanced adenomatous polyps (FORTE) NRG-CC005 study: A randomized phase III non-inferiority trial comparing colorectal cancer incidence in participants with 1-2 non-advanced adenomas randomized to a 5- and 10-year surveillance colonoscopy exam schedule versus a 10-year surveillance colonoscopy exam schedule.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3631

N/A

0DataRank · unranked

1 citations

Hanna Bandos, Douglas Corley, Jeff Dueker, Greg Yothers, Jinbing Bai +6 more

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad078

N/A

0DataRank · unranked

20 citations

Hanna Bandos, Priya Rastogi, Barry C. Lembersky, Jong‐Hyeon Jeong, Charles E. Geyer +11 more

Best practices and pragmatic approaches for patient-reported outcomes and quality of life measures in cancer clinical trials

JNCI Monographs(2025)10.1093/jncimonographs/lgae047

N/A

0DataRank · unranked

7 citations

Pedro A. Torres‐Saavedra, Eva Culakova, Heather Gunn, Minji K. Lee, Fenghai Duan +5 more

Analyses of adverse events and patient‐reported outcomes with the toxicity index in cancer clinical trials

Cancer(2025)10.1002/cncr.70086

N/A

0DataRank · unranked

1 citations

N. Lynn Henry, Hanna Bandos, Vinícius F. Calsavara, Reena S. Cecchini, Márcio A. Diniz +8 more